Merck discontinues development of possible COVID-19 vaccines following results
Kenilworth-based Merck has announced the company is discontinuing development of its COVID-19 vaccine candidates, V590 and V591.
The decision follows the company’s review of findings from Phase 1 clinical studies for the vaccines.
In the studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.
The company now plans to focus its COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.
For more information, click here.